Baidu
map

Liver Transpl:儿童肝移植罕见并发症:膈疝

2014-12-18 MedSci MedSci原创

研究背景: 膈疝(diaphragmatic hernia ,DH)是儿童肝移植后罕见的并发症,获得性的DH应该被早期诊断和急诊手术修补,否则将是致命性的。其发病原因包括:横膈的神经损伤、术后腹水、增高的腹内压、移植物大小的不匹配、受体状态、营养不良、损伤修复延迟等。 研究方法: 回归性研究了1989年10月-2013年8月1032例儿童肝移植的临床资料,其中有10例DH患者,评估DH的危险

Figure 1. Computed tomography scan of a right-sided DH. The small and large bowels occupy the right hemithorax.

Figure 2. Surgical repair of a DH.

研究背景:

膈疝(diaphragmatic hernia ,DH)是儿童肝移植后罕见的并发症,获得性的DH应该被早期诊断和急诊手术修补,否则将是致命性的。其发病原因包括:横膈的神经损伤、术后腹水、增高的腹内压、移植物大小的不匹配、受体状态、营养不良、损伤修复延迟等。

研究方法:

回归性研究了1989年10月-2013年8月1032例儿童肝移植的临床资料,其中有10例DH患者,评估DH的危险因素。

研究结果:

1032例患者的肝移植的主要病因为肝外胆道闭锁(EHBA;488人, 47.3%)、急性肝衰竭(ALF; 135人,13.1%)、胆汁淤积性肝病(66人、6.4%)。10例DH患者中有4例EHBA(移植前已行Kasai肝门胆肠吻合),2例新生儿肝炎,1例不明原因的ALF,1例Ⅱ型进行性家族性的肝内胆汁淤积,1例Ⅰ型原发性高草酸盐尿症,1例血管内皮瘤。10例DH患者中7例尸体供肝,3例活体肝移植,移植肝平均重量248±41g,移植受体体重比(graft-to-recipient body weight ratio,GBWR)3.0%±1.22%,平均冷缺血时间510.70±307.67分钟。从肝移植到确诊DH的平均时间3.8±4.5年,DH患者的平均年龄4.9±4.6岁,诊断DH的临床症状包括小肠梗阻(1例),大肠梗阻(3例),持续性咳嗽(1例),发热(1例)、持续性胆汁淤积(1例),1例因探查吻合性胆道狭窄的剖腹手术偶然发现。10例DH内容物包括右结肠(2例),右结肠和小肠(2例),小肠(6例)。

结论:

DH发病的危险因素包括高GBWR,劈裂式肝移植物,年龄小。

原始出处

Cortes M1, Tapuria N, Khorsandi SE, Ibars EP, Vilca-Melendez H, Rela M, Heaton ND.Diaphragmatic hernia after liver transplantation in children: Case series and review of the literature.Liver Transpl. 2014 Dec;

本文来自MedSci编译,转载请注明出处,谢谢!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1643124, encodeId=08eb1643124ef, content=<a href='/topic/show?id=dce128402e5' target=_blank style='color:#2F92EE;'>#儿童肝移植#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28402, encryptionId=dce128402e5, topicName=儿童肝移植)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=356523117313, createdName=neurowu, createdTime=Thu Sep 17 18:09:00 CST 2015, time=2015-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656643, encodeId=77fc165664362, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Wed Feb 18 13:09:00 CST 2015, time=2015-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757642, encodeId=e40a1e5764238, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Tue Jun 02 12:09:00 CST 2015, time=2015-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467077, encodeId=e74d146e07729, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Sat Dec 20 08:09:00 CST 2014, time=2014-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517490, encodeId=3ac1151e490fc, content=<a href='/topic/show?id=08dbe042428' target=_blank style='color:#2F92EE;'>#疝#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70424, encryptionId=08dbe042428, topicName=疝)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5b7011086586, createdName=ms4657536712156177, createdTime=Sat Dec 20 08:09:00 CST 2014, time=2014-12-20, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1643124, encodeId=08eb1643124ef, content=<a href='/topic/show?id=dce128402e5' target=_blank style='color:#2F92EE;'>#儿童肝移植#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28402, encryptionId=dce128402e5, topicName=儿童肝移植)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=356523117313, createdName=neurowu, createdTime=Thu Sep 17 18:09:00 CST 2015, time=2015-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656643, encodeId=77fc165664362, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Wed Feb 18 13:09:00 CST 2015, time=2015-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757642, encodeId=e40a1e5764238, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Tue Jun 02 12:09:00 CST 2015, time=2015-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467077, encodeId=e74d146e07729, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Sat Dec 20 08:09:00 CST 2014, time=2014-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517490, encodeId=3ac1151e490fc, content=<a href='/topic/show?id=08dbe042428' target=_blank style='color:#2F92EE;'>#疝#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70424, encryptionId=08dbe042428, topicName=疝)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5b7011086586, createdName=ms4657536712156177, createdTime=Sat Dec 20 08:09:00 CST 2014, time=2014-12-20, status=1, ipAttribution=)]
    2015-02-18 bsmagic9140
  3. [GetPortalCommentsPageByObjectIdResponse(id=1643124, encodeId=08eb1643124ef, content=<a href='/topic/show?id=dce128402e5' target=_blank style='color:#2F92EE;'>#儿童肝移植#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28402, encryptionId=dce128402e5, topicName=儿童肝移植)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=356523117313, createdName=neurowu, createdTime=Thu Sep 17 18:09:00 CST 2015, time=2015-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656643, encodeId=77fc165664362, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Wed Feb 18 13:09:00 CST 2015, time=2015-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757642, encodeId=e40a1e5764238, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Tue Jun 02 12:09:00 CST 2015, time=2015-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467077, encodeId=e74d146e07729, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Sat Dec 20 08:09:00 CST 2014, time=2014-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517490, encodeId=3ac1151e490fc, content=<a href='/topic/show?id=08dbe042428' target=_blank style='color:#2F92EE;'>#疝#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70424, encryptionId=08dbe042428, topicName=疝)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5b7011086586, createdName=ms4657536712156177, createdTime=Sat Dec 20 08:09:00 CST 2014, time=2014-12-20, status=1, ipAttribution=)]
    2015-06-02 丁鹏鹏
  4. [GetPortalCommentsPageByObjectIdResponse(id=1643124, encodeId=08eb1643124ef, content=<a href='/topic/show?id=dce128402e5' target=_blank style='color:#2F92EE;'>#儿童肝移植#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28402, encryptionId=dce128402e5, topicName=儿童肝移植)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=356523117313, createdName=neurowu, createdTime=Thu Sep 17 18:09:00 CST 2015, time=2015-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656643, encodeId=77fc165664362, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Wed Feb 18 13:09:00 CST 2015, time=2015-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757642, encodeId=e40a1e5764238, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Tue Jun 02 12:09:00 CST 2015, time=2015-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467077, encodeId=e74d146e07729, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Sat Dec 20 08:09:00 CST 2014, time=2014-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517490, encodeId=3ac1151e490fc, content=<a href='/topic/show?id=08dbe042428' target=_blank style='color:#2F92EE;'>#疝#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70424, encryptionId=08dbe042428, topicName=疝)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5b7011086586, createdName=ms4657536712156177, createdTime=Sat Dec 20 08:09:00 CST 2014, time=2014-12-20, status=1, ipAttribution=)]
    2014-12-20 syscxl
  5. [GetPortalCommentsPageByObjectIdResponse(id=1643124, encodeId=08eb1643124ef, content=<a href='/topic/show?id=dce128402e5' target=_blank style='color:#2F92EE;'>#儿童肝移植#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28402, encryptionId=dce128402e5, topicName=儿童肝移植)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=356523117313, createdName=neurowu, createdTime=Thu Sep 17 18:09:00 CST 2015, time=2015-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656643, encodeId=77fc165664362, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Wed Feb 18 13:09:00 CST 2015, time=2015-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757642, encodeId=e40a1e5764238, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Tue Jun 02 12:09:00 CST 2015, time=2015-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467077, encodeId=e74d146e07729, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Sat Dec 20 08:09:00 CST 2014, time=2014-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517490, encodeId=3ac1151e490fc, content=<a href='/topic/show?id=08dbe042428' target=_blank style='color:#2F92EE;'>#疝#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70424, encryptionId=08dbe042428, topicName=疝)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5b7011086586, createdName=ms4657536712156177, createdTime=Sat Dec 20 08:09:00 CST 2014, time=2014-12-20, status=1, ipAttribution=)]

相关资讯

Liver Transpl:肝移植--“肝性脑病之殇”

Figure 3. Overall 90-day wait-list survival stratified by degree of HE 研究背景: 终末期肝病模型(Model for end stage liver disease,MELD)常用于评估终末期肝病患者病情的严重程度和等待肝移植的优先次序,但是MELD模型并不包括肝性脑病(Hepatic Encephalopathy,H

丙肝肝移植患者抗病毒治疗新方案—更快、更安全

接受肝移植的丙肝患者的新肝组织最终都会出现感染。在这些移植的组织严重受损前需进行抗病毒治疗,但是传统的移植后治疗时间长达一年,存在潜在毒性并且可能导致器官排斥反应。最近,在美国肝病研究协会(The Liver Meeting® 2014)上,梅奥诊所的研究者报道:肝移植后采用两种新的口服药物治疗,安全有效并且治疗只需12周即可完成。该项研究的负责人Pungpapong博士说:“该研究是首个在肝移植

2014中国肝癌肝移植临床实践指南

肝移植是被全世界认可的治疗终末期肝病的有效手段之一。目前,肝移植在全国范围内已得到广泛开展,亟待相关临床实践指南来指导全国肝移植工作更规范、有效、安全地开展。中华医学会器官移植学分会、中华医学会外科学分会移植学组及中国医师协会器官移植医师分会组织专家制订了《中国肝癌肝移植临床实践指南(2014版)》,重点阐述肝移植受者选择标准、术前降期治疗、受者抗病毒治疗、受者免疫抑制剂应用、术后肿瘤复发的防治5

EASL 2014:Sofosbuvir可有效治疗肝移植术后HCV的复发

目前没有有效治疗肝移植术后丙型肝炎复发的方案。在2014年4月11日的EASL2014会议上,巴塞罗那的研究人员报道,核苷酸聚合酶抑制剂sofosbuvir(SOF)对于多种HCV基因型,不同的患者人群均有效。它的耐药屏障较高,且不会与免疫抑制剂发生相互作用,具有良好的安全性。 该研究的目标人群是肝移植术后复发重症HCV的患者。这些患者已经使用了各种治疗方案,但临床预后较差。基于SOF的治疗方案可

EASL 2014:肝移植供体因素应纳入移植术后HCC复发因素中

肝细胞癌(HCC)在移植术后复发率约为10%-15%。迄今为止的研究多关注于移植术接受者本身的特征因素对术后复发的影响,而较少关注于移植供体者的特点对接受者术后复发的影响。 瑞士日内瓦大学医院移植外科Orci等进行了一项研究,旨在探讨供体特征和供肝质量对接受者移植术后复发的风险影响。 该研究的对象为2004年至2011年间接受肝移植术的患者,进行多因素Cox比例风险回归分析。结果显示,9724例接

J Hepatol:高风险肝源使用量上升与肝移植术后急性肾损伤率增加有关

肝移植手术肝源供需之间的差距日益增大,因此有必要寻找其他措施来扩大供体库。由于等待移植患者群死亡率逐渐攀升,移植计划不得已越来越依赖“放宽肝源供体标准”或采用“高风险”肝源。 美国国家统计证实,老年捐肝者和循环衰竭死亡后捐肝者(DCD)的比例逐年上升,在捐肝者减少的趋势下分别占肝源总数的13%和5%;而英国捐肝者则相对更低、等待移植者死亡率较高,其中29%肝源供体年龄超过60岁,19%肝源来

Baidu
map
Baidu
map
Baidu
map